Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel

    April 2024 in “ Frontiers in medicine ”
    Lidia Rudnicka, Magdalena Trzeciak, Erkan Alpsoy … Burcu Gürbüz
    Studysummary This Delphi study found that moderate-to-severe alopecia areata in Poland, Czechia, Russia, and Türkiye significantly impacts quality of life and highlights an unmet need for more effective treatments.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 22

    1. Janus Kinase Inhibitors For Alopecia Areata JAMA network open · 2023
    2. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women With Alopecia: A Retrospective Study Journal of The American Academy of Dermatology · 2023
    3. The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata Dermatology and Therapy · 2022
    4. Emerging Drugs for the Treatment of Alopecia Areata Expert opinion on emerging drugs · 2022
    5. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    6. The Associated Burden of Mental Health Conditions in Alopecia Areata: A Population-Based Study in UK Primary Care British Journal of Dermatology · 2022
    7. Alopecia Areata: Current Understanding and Management Journal der Deutschen Dermatologischen Gesellschaft · 2022
    8. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    9. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    10. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    11. Perception of Hair Loss and Education Increases Treatment Willingness in Patients With Androgenetic Alopecia: A Population-Based Study Annals of Dermatology · 2018
    12. Quality of Life with Alopecia Areata Versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29 Annals of Dermatology · 2018
    13. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    14. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    15. Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata Journal of The American Academy of Dermatology · 2017
    16. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    17. Quality of Life in Alopecia Areata: A Sample of Tunisian Patients Dermatology Research and Practice · 2013
    18. Is Trichoscopy a Reliable Tool to Diagnose Early Female Pattern Hair Loss? International Journal of Trichology · 2013
    19. Value of Trichoscopy Versus Trichogram for Diagnosis of Female Androgenetic Alopecia International Journal of Trichology · 2012
    20. Clinical Severity Does Not Reliably Predict Quality of Life in Women With Alopecia Areata, Telogen Effluvium, or Androgenic Alopecia Journal of The American Academy of Dermatology · 2011
    21. Alopecia Areata Update Journal of the American Academy of Dermatology · 2010
    22. Alopecia Areata Update Journal of The American Academy of Dermatology · 2010